Traditional Cardiac Risk Factors in Individuals with Chronic Kidney Disease

Seminars in Dialysis

Volumn 16, Issue 2, 2003, Pages 118-127

  Uhlig, Katrin ^a   Levey, Andrew S ^a   Sarnak, Mark J ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYCLOSPORIN; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINE; NITRIC OXIDE; PHOSPHATE; PRAVASTATIN; RAPAMYCIN; SIMVASTATIN; TSUKUBAENOLIDE;

AGE; ANEMIA; ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMORBIDITY; CORRELATION ANALYSIS; DIABETES MELLITUS; DISEASE COURSE; DRUG INDICATION; DRUG SAFETY; DYSLIPIDEMIA; ELECTROLYTE DISTURBANCE; EXERCISE; EXTRACELLULAR SPACE; FAMILY HISTORY; GENDER; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS PATIENT; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALNUTRITION; MENOPAUSE; METABOLIC DISORDER; MYOSITIS; NICOTINE REPLACEMENT THERAPY; OXIDATIVE STRESS; PHYSICAL ACTIVITY; PREVALENCE; PROTEINURIA; RECIPIENT; REVIEW; RISK FACTOR; SIDE EFFECT; SLEEP DISORDER; SMOKING; SMOKING CESSATION; THROMBOGENESIS; CHRONIC DISEASE; CONTROLLED CLINICAL TRIAL; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; HYPERLIPIDEMIA; KIDNEY DISEASE; MORTALITY; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY;

CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; KIDNEY DISEASES; RANDOMIZED CONTROLLED TRIALS; RENAL DIALYSIS; RISK FACTORS;

EID: 0042073221     PISSN: 08940959     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-139X.2003.16028.x     Document Type: Review

References (123)

1. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, Klag MJ, Mailloux LU, Manske CL, Meyer KB, Parfrey PS, Pfeffer MA, Wenger NK, Wilson PW, Wright JT Jr: Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 32:853-906, 1998
2. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 39:S1-S246, 2002
3. Sarnak MJ, Levey AS: Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis 35:S117-S131, 2000
4. Parfrey PS, Foley RN: The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 10:1606-1615, 1999
5. Anderson KM, Wilson PWF, Odell PM, Kannel WB: An updated coronary risk profile: a statement for health professionals. Circulation 83:356-362, 1991
6. Brittain E: Probability of coronary heart disease developing. West J Med 136:86-89, 1982
7. Sarnak MJ, Coronado BE, Greene T, Wang SR, Kusek JW, Beck GJ, Levey AS: Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol 57:327-335, 2002
8. Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, Klag MJ: Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE study. J Am Soc Nephrol 13:1918-1927, 2002
9. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, Teehan BP, Levey AS: Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 58:353-362, 2000
10. Kasiske BL, Chakkera HA, Roel J: Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 11:1735-1743, 2000
11. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray D, Barre PE: Outcome and risk factors of ischemic heart disease in chronic uremia. Kidney Int 49:1428-1434, 1996
12. Wu G: Cardiovascular deaths among CAPD patients. Peritoneal Dial Bull 4(suppl):S23-S26, 1983
13. Rostand SG, Gretes JC, Kirk KA, Rutsky EA, Andreoli TE: Ischemic heart disease in patients with uremia undergoing maintenance hemodialysis. Kidney Int 16:600-611, 1979
14. Kasiske BL: Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis 32:S142-S156, 1998
15. Tonelli M, Bohm C, Pandeya S, Gill J, Levin A, Kiberd BA: Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis 37:484-489, 2001
16. Jungers P, Massy ZA, Khoa TN, Fumeron C, Labrunie M, Lacour B, Descamps-Latscha B, Man NK: Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study. Nephrol Dial Transplant 12:2597-2602, 1997
17. Ligtenberg G, Hene RJ, Blankestijn PJ, Koomans HA: Cardiovascular risk factors in renal transplant patients: cyclosporin A versus tacrolimus. J Am Soc Nephrol 12:368-373, 2001
18. Collins AJ, Li S, Ma JZ, Herzog C: Cardiovascular disease in end-stage renal disease patients. Am J Kidney Dis 38:S26-S29, 2001
19. Kasiske BL, Guijarro C. Massy ZA, Wiederkehr MR, Ma JZ: Cardiovascular disease after renal transplantation. J Am Soc Nephrol 7:158-165, 1996
20. Shoji T, Ishimura E, Inaba M, Tabata T, Nishizawa Y: Atherogenic lipoproteins in end-stage renal disease. Am J Kidney Dis 38:S30-S33, 2001
21. Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, Stehman-Breen CO: HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 61:297-304, 2002
22. Stack AG, Bloembergen WE: Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: a cross-sectional study. J Am Soc Nephrol 12:1516-1523, 2001
23. Tschope W, Koch M, Thomas B, Ritz E: Serum lipids predict cardiac death in diabetic patients on maintenance hemodialysis. Results of a prospective study. The German Study Group Diabetes Uremia. Nephron 64:354-358, 1993
24. Lowrie EG, Lew NL: Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 25:458-482, 1990
25. Iseki K, Yamazato M, Tozawa M, Takishita S: Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 61:1887-1893, 2002
26. Saltissi D, Morgan C, Rigby RJ, Westhuyzen J: Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. Am J Kidney Dis 39:283-290, 2002
27. Harris KP, Wheeler DC, Chong CC: A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD. Kidney Int 61:1469-1474, 2002
28. Hufnagel G, Michel C, Vrtovsnik F, Queffeulou G, Kossari N, Mignon F: Effects of atorvastatin on dyslipidaemia in uraemic patients on peritoneal dialysis. Nephrol Dial Transplant 15:684-688, 2000
29. Holdaas H, Jardine AG, Wheeler DC, Brekke IB, Conlon PJ, Fellstrom B, Hammad A, Holme I, Isoniemi H, Moore R, Rowe PA, Sweny P, Talbot DA, Wadstrom J, Ostraat O: Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney Int 60:1990-1997, 2001
30. Arnadottir M, Eriksson LO, Germershausen JI, Thysell H: Low-dose simvastatin is a well-tolerated and efficacious cholesterol-lowering agent in cyclosporine-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients. Nephron 68:57-62, 1994
31. Diercks GF, Janssen WM, van Boven AJ, Bak AA, de Jong PE, Crijns HJ, van Gilst WH: Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT]). Am J Cardiol 86:635-638, 2000
32. Holdaas H, Fellstrom B, Holme I, Nyberg G, Fauchald P, Jardine A, Gronhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Weinreich T, Olsson AG, Pedersen TR, Benghozi R, Hartmann A: Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data. J Cardiovasc Risk 8:63-71, 2001
33. Wanner C, Krane V, Ruf G, Marz W, Ritz E: Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators. Kidney Int Suppl 71:S222-S226, 1999
34. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 269:3015-3023, 1993
35. Coresh J, Wei GL, McQuillan G, Brancati FL, Levey AS, Jones C, Klag MJ: Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 161:1207-1216, 2001
36. Buckalew VM Jr, Berg RL, Wang SR, Porush JG, Rauch S, Schulman G: Prevalence of hypertension in 1,795 subjects with chronic renal disease: the modification of diet in renal disease study baseline cohort. Modification of Diet in Renal Disease Study Group. Am J Kidney Dis 28:811-821, 1996
37. Shoji T, Emoto M, Tabata T, Kimoto E, Shinohara K, Maekawa K, Kawagishi T, Tahara H, Ishimura E, Nishizawa Y: Advanced atherosclerosis in predialysis patients with chronic renal failure. Kidney Int 61:2187-2192, 2002
38. Tonelli M, Gill J, Pandeya S, Bohm C, Levin A, Kiberd BA: Barriers to blood pressure control and angiotensin enzyme inhibitor use in Canadian patients with chronic renal insufficiency. Nephrol Dial Transplant 17:1426-1433, 2002
39. Levin A, Singer J, Thompson CR, Ross H, Lewis M: Prevalent left venticular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 27:347-354, 1996
40. Lazarus JM, Bourgoignie JJ, Buckalew VM, Greene T, Levey AS, Milas NC, Paranandi L, Peterson JC, Porush JG, Rauch S, Soucie JM, Stollar C: Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group. Hypertension 29:641-650, 1997
41. Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16:434-444, 1993
42. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321:412-419, 2000
43. Davis TM, Millns H, Stratton IM, Holman RR, Turner RC: Risk factors for stroke in type 2 diabetes mellitus. United Kingdom Prospective Diabetes Study (UKPDS) 29. Arch Intern Med 159:1097-1103, 1999
44. Kasiske BL, Kalil RS, Ma JZ, Liao M, Keane WF: Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 118:129-138, 1993
45. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Eng J Med 329:1456-1462, 1993
46. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
47. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
48. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878, 2001
49. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 349:1857-1863, 1997
50. Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G: Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354:359-364, 1999
51. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 334:939-945, 1996
52. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, Maschio G, Brenner BM, Kamper A, Zucchelli P, Becker G, Himmelmann A, Bannister K, Landais P, Shahinfar S, de Jong PE, de Zeeuw D, Lau J, Levey AS: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 135:73-87, 2001
53. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 134:629-636, 2001
54. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek D, Cleveland W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y, Hebert L, Hiremath L, Jamerson K, Johnson CJ, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller ER III, Norris K, O'Connor D, Ojo A, Phillips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schulman G, Smith W, Thornley-Brown D, Tisher CC, Toto RD, Wright JT Jr, Xu S: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 285:2719-2728, 2001
55. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338:645-652, 1998
56. Ruggenenti P, Perna A, Benini R, Remuzzi G: Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). J Am Soc Nephrol 9:2096-2101, 1998
57. The sixth report of the Joint National Committee on prevention, detection evaluation, and treatment of high blood pressure. Arch Intern Med 157:2413-2446, 1997
58. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J: Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 36:646-661, 2000
59. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351:1755-1762, 1998
60. Estacio RO, Jeffers BW, Gifford N, Schrier RW: Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 23(suppl 2):B54-B64, 2000
61. Aakhus S, Dahl K, Wideroe TE: Cardiovascular morbidity and risk factors in renal transplant patients. Nephrol Dial Transplant 14:648-654, 1999
62. Warholm C, Wilczek H, Pettersson E: Hypertension two years after renal transplantation: causes and consequences. Transplant Int 8:286-292, 1995
63. Schwenger V, Zeier M, Ritz E: Hypertension after renal transplantation. Ann Transplant 6:25-30, 2001
64. First MR, Neylan JF, Rocher LL, Tejani A: Hypertension after renal transplantation. J Am Soc Nephrol 4:S30-S36, 1994
65. Rigatto C, Parfrey P, Foley R, Negrijn C, Tribula C, Jeffery J: Congestive heart failure in renal transplant recipients: risk factors, outcomes, and relationship with ischemic heart disease. J Am Soc Nephrol 13:1084-1090, 2002
66. Mailloux LU, Levey AS: Hypertension in patients with chronic renal disease. Am J Kidney Dis 32:S120-S141, 1998
67. Kasiske BL, Vazquez MA, Harmon WE, Brown RS, Danovitch GM, Gaston RS, Roth D, Scandling JD, Singer GG: Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 11(suppl 15):S1-S86, 2000
68. Hausberg M, Barenbrock M, Hohage H, Muller S, Heidenreich S, Rahn KH: ACE inhibitor versus beta-blocker for the treatment of hypertension in renal allograft recipients. Hypertension 33:862-868, 1999
69. Midtvedt K, Ihlen H, Hartmann A, Bryde P, Bjerkely BL, Foss A, Fauchald P, Holdaas H: Reduction of left ventricular mass by lisinopril and nifedipine in hypertensive renal transplant recipients: a prospective randomized double-blind study. Transplantation 72:107-111, 2001
70. Suwelack B, Gerhardt U, Hausberg M, Rahn KH, Hohage H: Comparison of quinapril versus atenolol: effects on blood pressure and cardiac mass after renal transplantation. Am J Cardiol 86:583-585 A510, 2000
71. Klingbeil AU, Muller HJ, Delles C, Fleischmann E, Schmieder RE: Regression of left ventricular hypertrophy by AT1 receptor blockade in renal transplant recipients. Am J Hypertens 13:1295-1300, 2000
72. Mailloux LU, Haley WE: Hypertension in the ESRD patient: pathophysiology, therapy, outcomes, and future directions. Am J Kidney Dis 32:705-719, 1998
73. Menon MK, Naimark DM, Bargman JM, Vas SI, Oreopoulos DG: Long-term blood pressure control in a cohort of peritoneal dialysis patients and its association with residual renal function. Nephrol Dial Transplant 16:2207-2213, 2001
74. Salem MM: Hypertension in the hemodialysis population: a survey of 649 patients. Am J Kidney Dis 26:461-468, 1995
75. Rahman M, Dixit A, Donley V, Gupta S, Hanslik T, Lacson E, Ogundipe A, Weigel K, Smith MC: Factors associated with inadequate blood pressure control in hypertensive hemodialysis patients. Am J Kidney Dis 33:498-506, 1999
76. Rocco MV, Van G, Heyka RJ, Benz R, Cheung AK: Risk factors for hypertension in chronic hemodialysis patients: baseline data from the HEMO study. Am J Nephrol 21:280-288, 2001
77. Mittal SK, Kowalski E, Trenkle J, McDonough B, Halinski D, Devlin K, Boylan E, Flaster E, Maesaka JK: Prevalence of hypertension in a hemodialysis population. Clin Nephrol 51:77-82, 1999
78. Rocco MV, Flanigan MJ, Beaver S, Frederick P, Gentile DE, McClellan WM, Polder J, Prowant BF, Taylor L, Helgerson SD: Report from the 1995 Core Indicators for Peritoneal Dialysis Study Group. Am J Kidney Dis 30:165-173, 1997
79. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 49:1379-1385, 1996
80. Kawamura M, Fijimoto S, Hisanaga S, Yamamoto Y, Eto T: Incidence, outcome, and risk factors of cerebrovascular events in patients undergoing maintenance hemodialysis. Am J Kidney Dis 31:991-996, 1998
81. Charra B, Calemard E, Ruffet M, Chazot C, Terrat JC, Vanel T, Laurent G: Survival as an index of adequacy of dialysis. Kidney Int 41:1286-1291, 1992
82. Chan CT, Floras JS, Miller JA, Richardson RM, Pierratos A: Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int 61:2235-2239, 2002
83. Zager PG, Nikolic J, Brown RH, Campbell MA, Hunt WC, Peterson D, Van Stone J, Levey A, Meyer KB, Klag MJ, Johnson KH, Clark E, Sadler JH, Teredesai P: "U" curve association of blood pressure and mortality in hemodialysis patients. Kidney Int 54:561-569, 1998
84. Port FK, Hulbert-Shearon TE, Wolfe RA, Bloembergen WE, Golper TA, Agodoa LY, Young EW: Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis 33:507-517, 1999
85. Coresh J, Longenecker JC, Miller ER III, Young HJ, Klag MJ: Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol 9:S24-S30, 1998
86. London GM, Pannier B, Guerin AP, Marchais SJ, Safar ME, Cuche JL: Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation 90:2786-2796, 1994
87. Cannella G, Paoletti E, Delfino R, Peloso G, Molinari S, Traverso GB: Regression of left ventricular hypertrophy in hypertensive dialyzed uremic patients on long-term antihypertensive therapy. Kidney Int 44:881-886, 1993
88. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145-153, 2000
89. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:1004-1010, 2002
90. Orth SR, Ritz E, Schrier RW: The renal risks of smoking. Kidney Int 51:1669-1677, 1997
91. Krijnen P, van Jaarsveld BC, Steyerberg EW, Man in't Veld AJ, Schalekamp MA, Habbema JD: A clinical prediction rule for renal artery stenosis. Ann Intern Med 129:705-711, 1998
92. Kasiske BL, Klinger D: Cigarette smoking in renal transplant recipients. J Am Soc Nephrol 11:753-759, 2000
93. Held PJ, Port FK, Gaylin DS, Wolfe RA, Levin NW, Blagg CR, Garcia J, Agodoa L: Comorbid conditions and correlations with mortality risk among 3,399 incident hemodialysis patients. Am J Kidney Dis 20:32-38, 1992
94. U.S. Renal Data System: USRDS 1997 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1997
95. Beto JA, Bansal VK: Interventions for other risk factors: tobacco use, physical inactivity, menopause, and homocysteine. Am J Kidney Dis 5(suppl 3):S172-S184, 1998
96. Anderson JE, Jorenby DE, Scott WJ, Fiore MC: Treating tobacco use and dependence: an evidence-based clinical practice guideline for tobacco cessation. Chest 121:932-941, 2002
97. Molander L, Hansson A, Lunell E, Alainentalo L, Hoffmann M, Larsson R: Pharmacokinetics of nicotine in kidney failure. Clin Pharmacol Ther 68:250-260, 2000
98. Aronoff GR, Berns JS, Brier ME, Golper TA, Morrison G, Singer I, Swan SK, Bennett WM: Drug Prescribing in Renal Failure, 4th ed. : American College of Physicians, Philadelphia, PA, 1999
99. Stephenson JM, Kenny S, Stevens LK, Fuller JH, Lee E: Proteinuria and mortality in diabetes: the WHO Multinational Study of Vascular Disease in Diabetes. Diabet Med 12:149-155, 1995
100. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney Int 47:1703-1720, 1995
101. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837-853, 1998
102. Retinopathy, nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control, Complications Trial/Epidemiology of Diabetes Interventions, Complications Research Group. N Engl J Med 342:381-389, 2000
103. Kasiske BL: Epidemiology of cardiovascular disease after renal transplantation. Transplantation 72:S5-S8, 2001
104. Barbosa J, Steffes MW, Sutherland DE, Connett JE, Rao KV, Mauer SM: Effect of glycemic control on early diabetic renal lesions. A 5-year randomized controlled clinical trial of insulin-dependent diabetic kidney transplant recipients. JAMA 272:600-606, 1994
105. Becker BN, Brazy PC, Becker YT, Odorico JS, Pintar TJ, Collins BH, Pirsch JD, Leverson GE, Heisey DM, Sollinger HW: Simultaneous pancreas-kidney transplantation reduces excess mortality in type 1 diabetic patients with end-stage renal disease. Kidney Int 57:2129-2135, 2000
106. Tyden G, Bolinder J, Solders G, Brattstrom C, Tibell A, Groth CG: Improved survival in patients with insulin-dependent diabetes mellitus and end-stage diabetic nephropathy 10 years after combined pancreas and kidney transplantation. Transplantation 67:645-648, 1999
107. U.S. Renal Data System: USRDS 2000 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, Division of Kidney, Urologic, and Hematologic Diseases, 2000
108. Cano NJ, Roth H, Aparicio M, Azar R, Canaud B, Chauveau P, Combe C, Fouque D, Laville M, Leverve XM: Malnutrition in hemodialysis diabetic patients: evaluation and prognostic influence. Kidney Int 62:593-601, 2002
109. Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS: Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 47:884-890, 1995
110. Manske CL: Hyperglycemia and intensive glycemic control in diabetic patients with chronic renal disease. Am J Kidney Dis 32:S157-S171, 1998
111. Painter P, Messer-Rehak D, Hanson P, Zimmerman SW, Glass NR: Exercise capacity in hemodialysis, CAPD, and renal transplant patients. Nephron 42:47-51, 1986
112. Painter P: The importance of exercise training in rehabilitation of patients with end-stage renal disease. Am J Kidney Dis 24:S2-S9; discussion S31-32, 1994
113. Sietsema KE, Hiatt WR, Esler A, Adler S, Amato A, Brass EP: Clinical and demographic predictors of exercise capacity in end-stage renal disease. Am J Kidney Dis 39:76-85, 2002
114. Goldberg AP, Geltman EM, Gavin JR III, Carney RM, Hagberg JM, Delmez JA, Naumovich A, Oldfield MH, Harter HR: Exercise training reduces coronary risk and effectively rehabilitates hemodialysis patients. Nephron 42:311-316, 1986
115. Miller BW, Cress CL, Johnson ME, Nichols DH, Schnitzler MA: Exercise during hemodialysis decreases the use of antihypertensive medications. Am J Kidney Dis 39:828-833, 2002
116. Surgeon General's report on physical activity and health. From the Centers for Disease Control and Prevention. JAMA 276:522, 1996
117. Physical activity and cardiovascular health. NIH Consensus Development Panel on Physical Activity and Cardiovascular Health. JAMA 276:241-246, 1996
118. Painter P, Carlson L, Carey S, Paul SM, Myll J: Physical functioning and health-related quality-of-life changes with exercise training in hemodialysis patients. Am J Kidney Dis 35:482-492, 2000
119. Mercer TH, Crawford C, Gleeson NP, Naish PF: Low-volume exercise rehabilitation improves functional capacity and self-reported functional status of dialysis patients. Am J Phys Med Rehabil 81:162-167, 2002
120. Koufaki P, Mercer TH, Naish PF: Effects of exercise training on aerobic and functional capacity of end-stage renal disease patients. Clin Physiol Funct Imaging 22:115-124, 2002
121. Castaneda C, Gordon PL, Uhlin KL, Levey AS, Kehayias JJ, Dwyer JT, Fielding RA, Roubenoff R, Singh MF: Resistance training to counter-act the catabolism of a low-protein diet in patients with chronic renal insufficiency. A randomized, controlled trial. Ann Intern Med 135:965-976, 2001
122. Beto JA, Bansal VK: Interventions for other risk factors: tobacco use, physical inactivity, menopause, and homocysteine. Am J Kidney Dis 32:S172-S183, 1998
123. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Jama 288:2981-2997, 2002